We aim to provide better alternatives to patients around the globe &We fight daily because we know patients are too.
Our initial focus is on oral cancer followed by intra-opertaive chemotherapy and HPV caused cancers.
Privo's Phase II clinical study on oral cancer is near completion
Over 150 years of combined experience in life science and innovation (details)
Manijeh Goldberg, PhD, MBA CEO, Founder
Manijeh is the CEO and founder of Privo. She has over 25 years experience in lifesciences, leading product from concept to market
Dan Geffken, MBA Senior Financial Adviser
Dan has over 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle.
Edward Garmey, MD Interim CMO
Edward is an oncologist that has served as a CMO for leading private and public biopharmaceuticals for over 15 years
Sam Goldberger, MD, MBA Sr. Medical Monitor
Sam is a reconstructive surgeon with over 30 years of clinical experience as well as expertise in innovation and finance
Bruce Sunstein, JD, Intellectual Property
Bruce is a well-known Boston patent and IP strategist for market leaders and innovators in biopharma industries
Ruthanna Costello, RN, MS Clinical Operations
Ruthanna has over 30 years of clinical experience in managing and monitoring complex clinical research
Privo is excited to work closely with its collaborators at the FDA, the NCI and the NIDCR. Privo Technologies has received over $11M in nondilutive funding from these institutions in support of its product development and clinical trial.
Privo is currently recruiting subjects for its Phase II clinical trial